Recent Finacing
Recent Raise
Actithera develops radioligand therapies via a proprietary platform that integrates medicinal chemistry, radiochemistry, rational design and covalent targeting to optimize tumor residence and clearance, advancing a FAP-directed candidate to clinic.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
